Document is current
Any future updates will be listed below
-
Authors
Rask, Susanna Maria https://orcid.org/0009-0002-5118-6370
Solismaa, Anssi
Ahola-Olli, Ari
Molden, Espen https://orcid.org/0000-0001-6190-2751
O’Connell, Kevin Sean
Lyytikäinen, Leo-Pekka https://orcid.org/0000-0002-7200-5455
Mononen, Nina
Lehtimäki, Terho https://orcid.org/0000-0002-2555-4427
Kampman, Olli https://orcid.org/0000-0001-6891-2266
-
Funding
Funding for this research was provided by:
Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospitals (PIRHA) (grant X51001) and Signe and Ane Gyllenberg Foundation
- License Information
-
More Information
Article History
Received: 21 November 2024
Revised: 30 July 2025
Accepted: 11 September 2025
First Online: 24 October 2025
Competing interests
: Susanna Maria Rask, no conflicts of interest. Anssi Solismaa, no conflicts of interest. Ari Ahola-Olli is a shareholder and employee of Abomics, a company offering pharmacogenetics-related ICT solutions and consultation services. Espen Molden has received speaker´s honorarium from Lilly, Lundbeck and Otsuka. Kevin Sean O´Connell, no conflicts of interest. Leo-Pekka Lyytikäinen, no conflicts of interest. Nina Mononen, no conflicts of interest. Terho Lehtimäki, no conflicts of interest. Olli Kampman, no conflicts of interest.
